Company Profile: Complete Genomics
Overview
Complete Genomics is a pioneering biotechnology company headquartered in San Jose, California, specializing in DNA sequencing technologies and services since its founding in June 2005. The company's focus on massively parallel next-generation sequencing (NGS) and affordable whole-genome sequencing (WGS) underlines its mission to advance genomics and improve human health.
Mission and Vision
Complete Genomics is committed to creating accessible genomic solutions to revolutionize affordable sequencing and improve lives. By offering a complete range of genetic sequencers and lab automation equipment, the company accelerates scientific breakthroughs in various sectors, including healthcare and industrial applications.
Technology and Products
The company's proprietary DNBSEQ™ technology is renowned for its efficiency, accuracy, and PCR-free NGS solutions that minimize duplication rates and reduce costs. Their product line includes a variety of sequencing platforms, kits, reagents, and lab automation solutions. These innovations find applications in fields like neurology, oncology, and personalized medicine.
Leadership
Yongwei Zhang serves as the CEO of Complete Genomics and MGI Americas, with expertise in R&D, Operations, and Quality & Product Management. Alan Dow is the Vice President overseeing intellectual property. The company was co-founded by Clifford Reid, Radoje (Rade) Drmanac, who is also the Chief Scientific Officer, and John Curson.
Recent Developments
In 2024, Complete Genomics expanded its U.S. manufacturing capabilities with a new facility at its San Jose headquarters, supporting a robust domestic supply chain and reinforcing its ability to offer flexible and cost-effective sequencing solutions.
Strategic Importance
As a wholly-owned subsidiary of MGI, part of the BGI Group—the world's largest genomics service company—Complete Genomics benefits from enhanced global resources and collaborative R&D opportunities, strengthening its market position.
Contact Information
Complete Genomics' headquarters in San Jose can be contacted for genomic solutions:
- Address: 2904 Orchard Parkway, San Jose, California 95134
- Phone: 888-811-9644
Financials and Market Position
With an annual revenue of $28 million and approximately 255 employees, Complete Genomics is strategically positioned to challenge industry leaders such as Illumina. The company's upcoming advanced sequencers, capable of handling larger DNA volumes at reduced costs, underline a commitment to cost efficiency and scalability in DNA sequencing.
Competitors
Complete Genomics faces competition from:
- Illumina: A leader in the genetic sequencing market.
- Nabsys: Specialists in electronic genome mapping and solid-state sequencing technology.
- BC Platforms: Providers of real-world data solutions for genomics.
- Oxford Nanopore Technologies: Known for nanopore DNA/RNA sequencing scalability.
- OpGen: Focusing on molecular diagnostics for infectious diseases.
These competitors offer diverse solutions in sequencing, data management, and precision medicine, presenting varying technological approaches.
Strategy and Competitive Advantage
Complete Genomics aims to differentiate itself with advanced, cost-effective sequencing technology. By planning to introduce new high-capacity sequencers, the company seeks to attract partnerships with researchers and healthcare providers. Key strategic focuses include:
- Innovation: Investment in reducing costs and increasing sequencing throughput for broader application appeal.
- Target Markets: Leveraging unique technology aspects to penetrate niche markets sensitive to cost.
- Strategic Partnerships: Forming alliances to boost market presence and demonstrate the efficacy and cost benefits of new sequencers.
By concentrating on these areas, Complete Genomics positions itself to grow and compete effectively in the genomic research landscape.
